Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases. The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and Company and supported by existing […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!